Navigation Links
New MS drug proves effective where others have failed
Date:10/31/2012

A drug which 'reboots' a person's immune system has been shown to be an effective treatment for multiple sclerosis (MS) patients who have already failed to respond to the first drug with which they were treated (a 'first-line' therapy), as well as affected individuals who were previously untreated. The results of these two phase III clinical trials were published today in the journal The Lancet.

The new studies, sponsored by Genzyme (a Sanofi company) and Bayer Schering Pharma, showed that alemtuzumab significantly reduces the number of attacks (or relapses) experienced by people with MS compared to interferon beta-1a (known commercially as Rebif). This was seen both in patients who had not previously received any treatment (drug-nave) and those who have continued to show disease activity whilst taking an existing treatment for MS.

In the CARE MSII trial, confined to patients who had recently relapsed on a licenced therapy, new episodes were reduced by 49 per cent more than that achieved by the current standard treatment for MS, interferon beta-1a. Over a two year period, 65 per cent of patients on alemtuzumab compared to 47 per cent of patients on interferon remained relapse free. Additionally, alemtuzumab reduced the risk of acquiring disability by 42 per cent compared to interferon: disability worsened in 20% of interferon patients and 13% of alemtuzumab patients. Moreover, at the end of the study, on average, patients taking alemtuzumab had less disability than when they started the trial whereas those on interferon had experienced worsening disability.

"Our research shows the transformative effect that alemtuzumab can have for people with MS. Patients who continue to show disease activity while on their initial therapy are especially difficult to treat. Now, we have shown that alemtuzumab works where first-line drugs have already failed. It not only reduces the chances of disability associated with MS but may even result in
'/>"/>

Contact: Genevieve Maul
Genevieve.maul@admin.cam.ac.uk
44-012-237-65542
University of Cambridge
Source:Eurekalert

Page: 1 2 3 4

Related medicine news :

1. Clinical insight improves treatment with new lung cancer drug
2. Normalizing tumor blood vessels improves delivery of only the smallest nanomedicines
3. Chemotherapy proves life-saving for some leukemia patients who fail induction therapy
4. Exercise improves quality of life during breast cancer treatment
5. Early treatment improves outcomes in rare, often undiagnosed form of encephalitis
6. NYUCNs Dr. Laura Wagner: Study finds accreditation improves safety culture at nursing homes
7. Cone beam CT proves better for visualizing some causes of hearing loss at half the radiation dose
8. Brief training program improves resident physicians empathy with patients
9. FDA Approves Generic Versions of Plavix
10. A nurse practitioner-driven palliative care intervention improves cancer patients quality of life
11. Oxytocin improves brain function in children with autism
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... For decades, health-conscious people around the globe have taken ... this was one of the paths to good health ... trials of antioxidant supplements have repeatedly dashed the hopes ... cancer risk. Virtually all such trials have failed ... fact, in several trials antioxidant supplementation has been linked ...
(Date:7/10/2014)... the Bellvitge Biomedical Research Institute (IDIBELL) and the Catalan ... patients a new therapeutic combination to combat resistant sarcomas. ... treatment could stabilize the growth of these tumors have ... of Cancer ., Sarcomas , Sarcomas are a ... several subtypes. It can affect from children to older ...
(Date:7/10/2014)... new drug could prove useful in treating small cell lung ... Scientists from the Cancer Research UK Manchester Institute, based at ... Research Centre, teamed up with experts at AstraZeneca, as part ... known as AZD3965 - on small cell lung cancer ... Cancer Research , also helps identify which patients are most ...
(Date:7/9/2014)... you think winning is one of the key determinants that ... with other mental bonuses ranked near the bottom of 81 ... 11 big fun factors, according to a new study. Despite ... comes to the "fun" factor, very little research had been ... elusive conceptuntil now. , The results of this study might ...
(Date:7/9/2014)... acute episodes of low back pain are not linked ... wind direction and precipitation. Findings published in Arthritis ... College of Rheumatology (ACR), indicate that the risk of ... or wind gusts, but was not clinically significant. ... everyone experiences low back pain at some point in ...
Breaking Medicine News(10 mins):Health News:How antioxidants can accelerate cancers, and why they don't protect against them 2Health News:New therapeutic combination to slow resistant sarcomas 2Health News:New drug active against most aggressive type of lung cancer cells 2Health News:Being a good sport ranks as the top 'fun' factor in study of youth sports 2Health News:Being a good sport ranks as the top 'fun' factor in study of youth sports 3Health News:Low back pain? Don't blame the weather 2
... 27 Attorney General Michael,B. Mukasey will deliver the ... Ceremony and remarks on Justice,Department nationwide efforts to combat ... be held on WEDNESDAY, MAY 28, 2008., WHO: ... WHEN: WEDNESDAY, MAY 28, 2008, 1:00 P.M. ...
... Fla. Once heralded as a promising obesity treatment, ... discovered overweight patients were resistant to its effects. But ... seems to revive the hormones ability to fight fat ... The combination of leptin and a modest dose of ...
... Finer Senior Living Expected in Coming Years, SANTA ... and scenery at Varenna. Oakmont Senior Living LLC did ... that benefits from 25 years,of experience in every facet ... new continuing care residential community sets a grand,and unparalleled ...
... is not associated with a reduced risk of prostate ... 27 in the Journal of the National Cancer ... of vitamin D may reduce the risk of prostate ... have reported inconsistent results. , In a nested case-control ...
... finds evidence of slight link between higher concentrations, aggressive ... Men with a high blood concentration of vitamin D ... Cancer Institute researchers report. , Previous laboratory studies had ... prostate cancer risk, but epidemiological studies of that association ...
... completely unexpected way that the brain repairs nerve damage, wherein ... neurons. , Astrocytes are a type of support cell in ... is to chew up damaged nerves during brain injury and ... Roger Chung and colleagues have now found that astrocytes have ...
Cached Medicine News:Health News:Combining exercise with hormone could prevent weight gain 2Health News:Combining exercise with hormone could prevent weight gain 3Health News:Sonoma Developer Oakmount Senior Living Marries Architecture With Nature to Recreate Tuscany at Varenna 2Health News:Sonoma Developer Oakmount Senior Living Marries Architecture With Nature to Recreate Tuscany at Varenna 3Health News:No association found between vitamin D concentration in blood and risk of prostate cancer 2Health News:Vitamin D Status Not Associated With Lower Prostate Risk 2
(Date:1/15/2014)... Shire plc (LSE: SHP, NASDAQ: SHPG ... (OFT) approval condition to the announced tender offer for all of ... As a result of the waiver, the transaction is no longer ... offer on January 24, 2014 following the currently scheduled expiration time, ...
(Date:1/15/2014)... PALM BEACH GARDENS, Fla. , Jan. 15, 2014  In an ... C. difficile and TB in ambulances and other transport vehicles, an ... being used by rescue personnel for the first time. ... coming in contact with these deadly pathogens, West Palm ...
(Date:1/15/2014)... , Jan. 15, 2014 The Cadence Fitness ... Fitness Center by the Medical Fitness Association, a non-profit ... achieve their full potential. The Cadence Fitness & Health ... western suburbs and second in the Chicagoland area. ...
Breaking Medicine Technology:Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3Superbugs No Longer Ride In Rescue Vehicles 2Cadence Fitness & Health Center Certified as Medical Fitness Facility 2Cadence Fitness & Health Center Certified as Medical Fitness Facility 3
... 2010 STAAR Surgical Company (Nasdaq: STAA ... invasive ophthalmic products, today reported results for the third ... grew 6% to $13.2 million reflecting core product (IOLs ... decrease in defocused product revenue as compared to the ...
... Nov. 2, 2010 Kensey Nash Corporation (Nasdaq: ... investor conferences in November.   Michael Celano, ... presentation, at the Oppenheimer 21st Annual Healthcare Conference at ... at 2:10 p.m. (ET).  To hear the live webcast ...
Cached Medicine Technology:STAAR Surgical Reports Continued Double Digit Core Revenue Growth 2STAAR Surgical Reports Continued Double Digit Core Revenue Growth 3STAAR Surgical Reports Continued Double Digit Core Revenue Growth 4STAAR Surgical Reports Continued Double Digit Core Revenue Growth 5STAAR Surgical Reports Continued Double Digit Core Revenue Growth 6STAAR Surgical Reports Continued Double Digit Core Revenue Growth 7STAAR Surgical Reports Continued Double Digit Core Revenue Growth 8STAAR Surgical Reports Continued Double Digit Core Revenue Growth 9STAAR Surgical Reports Continued Double Digit Core Revenue Growth 10STAAR Surgical Reports Continued Double Digit Core Revenue Growth 11STAAR Surgical Reports Continued Double Digit Core Revenue Growth 12STAAR Surgical Reports Continued Double Digit Core Revenue Growth 13STAAR Surgical Reports Continued Double Digit Core Revenue Growth 14STAAR Surgical Reports Continued Double Digit Core Revenue Growth 15STAAR Surgical Reports Continued Double Digit Core Revenue Growth 16STAAR Surgical Reports Continued Double Digit Core Revenue Growth 17
Intended for the quantitative determination of iron in serum. Reaction: Endpoint. Wavelength: 595 nm. Linearity: 500 g/dL (89.5 mol/L). Two vials, liquid reagents....
HDL Cholesterol (PEG) Precip. Reagent + 5 ml of 50 mg/dl cholesterol std....
Intended for the in vitro precipitation of very low density and low density lipoproteins in serum or plasma. Single vial, dry powder precipitating reagent. Total cholesterol reagent not included....
Ammonia reagent is used for the quantitative and enzymatic determination of ammonia in human plasma....
Medicine Products: